Ironwood Pharmaceuticals raises full-year 2026 guidance following third quarter revenue and earnings beats

Ironwood Pharmaceuticals reported third quarter 2026 revenue of $133.0 million and GAAP diluted EPS of $0.36, both of which significantly exceeded analyst expectations. The results were primarily driven by a 3% increase in LINZESS U.S. net sales and improved commercial margins, prompting management to raise full-year financial guidance for the second consecutive quarter.

Key Highlights

• LINZESS U.S. net sales reached $324.9 million in the third quarter, surpassing the analyst estimate of $262.5 million due to 4.9% prescription demand growth.
• Management raised full-year 2026 LINZESS U.S. net sales guidance to a range of $1.20 to $1.25 billion, representing a year-over-year increase of more than 35%.
• Total operating expenses decreased to $39.9 million from $46.6 million in the prior year, driven by a sharp reduction in SG&A spending to $11.6 million.